Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 75

1.

Rationale and Strategies for Preserving Residual Kidney Function in Dialysis Patients.

Li T, Wilcox CS, Lipkowitz MS, Gordon-Cappitelli J, Dragoi S.

Am J Nephrol. 2019;50(6):411-421. doi: 10.1159/000503805. Epub 2019 Oct 18. Review.

2.

APOL1 Kidney Risk Variants and Cardiovascular Disease: An Individual Participant Data Meta-Analysis.

Grams ME, Surapaneni A, Ballew SH, Appel LJ, Boerwinkle E, Boulware LE, Chen TK, Coresh J, Cushman M, Divers J, Gutiérrez OM, Irvin MR, Ix JH, Kopp JB, Kuller LH, Langefeld CD, Lipkowitz MS, Mukamal KJ, Musani SK, Naik RP, Pajewski NM, Peralta CA, Tin A, Wassel CL, Wilson JG, Winkler CA, Young BA, Zakai NA, Freedman BI.

J Am Soc Nephrol. 2019 Oct;30(10):2027-2036. doi: 10.1681/ASN.2019030240. Epub 2019 Aug 5.

PMID:
31383730
3.

Magnitude of the Difference Between Clinic and Ambulatory Blood Pressures and Risk of Adverse Outcomes in Patients With Chronic Kidney Disease.

Ku E, Hsu RK, Tuot DS, Bae SR, Lipkowitz MS, Smogorzewski MJ, Grimes BA, Weir MR.

J Am Heart Assoc. 2019 May 7;8(9):e011013. doi: 10.1161/JAHA.118.011013.

4.

A new common functional coding variant at the DDC gene change renal enzyme activity and modify renal dopamine function.

Miramontes-Gonzalez JP, Hightower M, Zhang K, Kurosaki H, Schork AJ, Biswas N, Vaingankar S, Mahata M, Lipkowitz MS, Nievergelt CM, Baker DG, Ziegler MG, León-Jiménez D, González-Sarmiento R, Ichinose H, O'Connor DT.

Sci Rep. 2019 Mar 25;9(1):5055. doi: 10.1038/s41598-019-41504-7.

5.

Soluble Urokinase-Type Plasminogen Activator Receptor in Black Americans with CKD.

Luo S, Coresh J, Tin A, Rebholz CM, Chen TK, Hayek SS, Tracy M, Lipkowitz MS, Appel LJ, Levey AS, Inker LA, Reiser J, Grams ME.

Clin J Am Soc Nephrol. 2018 Jul 6;13(7):1013-1021. doi: 10.2215/CJN.13631217. Epub 2018 Jun 14.

6.

Serum 6-Bromotryptophan Levels Identified as a Risk Factor for CKD Progression.

Tin A, Nadkarni G, Evans AM, Winkler CA, Bottinger E, Rebholz CM, Sarnak MJ, Inker LA, Levey AS, Lipkowitz MS, Appel LJ, Arking DE, Coresh J, Grams ME.

J Am Soc Nephrol. 2018 Jul;29(7):1939-1947. doi: 10.1681/ASN.2017101064. Epub 2018 May 18.

7.

Chronic kidney disease, kidney transplantation and oxidative stress: a new look to successful kidney transplantation.

Tabriziani H, Lipkowitz MS, Vuong N.

Clin Kidney J. 2018 Feb;11(1):130-135. doi: 10.1093/ckj/sfx091. Epub 2017 Aug 16.

8.

APOL1 Risk Variants, Incident Proteinuria, and Subsequent eGFR Decline in Blacks with Hypertension-Attributed CKD.

Chen TK, Tin A, Peralta CA, Appel LJ, Choi MJ, Lipkowitz MS, Winkler CA, Estrella MM.

Clin J Am Soc Nephrol. 2017 Nov 7;12(11):1771-1777. doi: 10.2215/CJN.01180117. Epub 2017 Oct 19.

9.

A Classification Model to Predict the Rate of Decline of Kidney Function.

Subasi E, Subasi MM, Hammer PL, Roboz J, Anbalagan V, Lipkowitz MS.

Front Med (Lausanne). 2017 Jul 19;4:97. doi: 10.3389/fmed.2017.00097. eCollection 2017.

10.

A tripartite complex of suPAR, APOL1 risk variants and αvβ3 integrin on podocytes mediates chronic kidney disease.

Hayek SS, Koh KH, Grams ME, Wei C, Ko YA, Li J, Samelko B, Lee H, Dande RR, Lee HW, Hahm E, Peev V, Tracy M, Tardi NJ, Gupta V, Altintas MM, Garborcauskas G, Stojanovic N, Winkler CA, Lipkowitz MS, Tin A, Inker LA, Levey AS, Zeier M, Freedman BI, Kopp JB, Skorecki K, Coresh J, Quyyumi AA, Sever S, Reiser J.

Nat Med. 2017 Aug;23(8):945-953. doi: 10.1038/nm.4362. Epub 2017 Jun 26.

11.

APOL1 Risk Variants and Cardiovascular Disease: Results From the AASK (African American Study of Kidney Disease and Hypertension).

Chen TK, Appel LJ, Grams ME, Tin A, Choi MJ, Lipkowitz MS, Winkler CA, Estrella MM.

Arterioscler Thromb Vasc Biol. 2017 Sep;37(9):1765-1769. doi: 10.1161/ATVBAHA.117.309384. Epub 2017 Jun 1.

12.

Acute Kidney Injury and In-Hospital Mortality after Coronary Artery Bypass Graft versus Percutaneous Coronary Intervention: A Nationwide Study.

Shen W, Aguilar R, Montero AR, Fernandez SJ, Taylor AJ, Wilcox CS, Lipkowitz MS, Umans JG.

Am J Nephrol. 2017;45(3):217-225. doi: 10.1159/000455906. Epub 2017 Jan 31.

PMID:
28135709
13.

Strict blood pressure control associates with decreased mortality risk by APOL1 genotype.

Ku E, Lipkowitz MS, Appel LJ, Parsa A, Gassman J, Glidden DV, Smogorzewski M, Hsu CY.

Kidney Int. 2017 Feb;91(2):443-450. doi: 10.1016/j.kint.2016.09.033. Epub 2016 Dec 4.

14.

Bartonella Endocarditis and Pauci-Immune Glomerulonephritis: A Case Report and Review of the Literature.

Raybould JE, Raybould AL, Morales MK, Zaheer M, Lipkowitz MS, Timpone JG, Kumar PN.

Infect Dis Clin Pract (Baltim Md). 2016 Sep;24(5):254-260. Epub 2016 Mar 1. Review.

15.

BP Control and Long-Term Risk of ESRD and Mortality.

Ku E, Gassman J, Appel LJ, Smogorzewski M, Sarnak MJ, Glidden DV, Bakris G, Gutiérrez OM, Hebert LA, Ix JH, Lea J, Lipkowitz MS, Norris K, Ploth D, Pogue VA, Rostand SG, Siew ED, Sika M, Tisher CC, Toto R, Wright JT Jr, Wyatt C, Hsu CY.

J Am Soc Nephrol. 2017 Feb;28(2):671-677. doi: 10.1681/ASN.2016030326. Epub 2016 Aug 11.

16.

Analysis of ABCG2 and other urate transporters in uric acid homeostasis in chronic kidney disease: potential role of remote sensing and signaling.

Bhatnagar V, Richard EL, Wu W, Nievergelt CM, Lipkowitz MS, Jeff J, Maihofer AX, Nigam SK.

Clin Kidney J. 2016 Jun;9(3):444-53. doi: 10.1093/ckj/sfw010. Epub 2016 Apr 5.

17.

Combined Effects of GSTM1 Null Allele and APOL1 Renal Risk Alleles in CKD Progression in the African American Study of Kidney Disease and Hypertension Trial.

Bodonyi-Kovacs G, Ma JZ, Chang J, Lipkowitz MS, Kopp JB, Winkler CA, Le TH.

J Am Soc Nephrol. 2016 Oct;27(10):3140-3152. Epub 2016 Mar 3.

18.

Examination of Potential Modifiers of the Association of APOL1 Alleles with CKD Progression.

Chen TK, Choi MJ, Kao WH, Astor BC, Scialla JJ, Appel LJ, Li L, Lipkowitz MS, Wolf M, Parekh RS, Winkler CA, Estrella MM, Crews DC.

Clin J Am Soc Nephrol. 2015 Dec 7;10(12):2128-35. doi: 10.2215/CJN.05220515. Epub 2015 Oct 1.

19.

Association of the ADRB2 (rs2053044) polymorphism and angiotensin-converting enzyme-inhibitor blood pressure response in the African American Study of Kidney Disease and Hypertension.

Anthony EG, Richard E, Lipkowitz MS, Bhatnagar V.

Pharmacogenet Genomics. 2015 Sep;25(9):444-9. doi: 10.1097/FPC.0000000000000154.

PMID:
26111150
20.

Apolipoprotein L1: from obscurity to consistency to controversy.

Lipkowitz MS.

Kidney Int. 2015 Jan;87(1):14-7. doi: 10.1038/ki.2014.319.

21.

Estimating time to ESRD using kidney failure risk equations: results from the African American Study of Kidney Disease and Hypertension (AASK).

Grams ME, Li L, Greene TH, Tin A, Sang Y, Kao WH, Lipkowitz MS, Wright JT, Chang AR, Astor BC, Appel LJ.

Am J Kidney Dis. 2015 Mar;65(3):394-402. doi: 10.1053/j.ajkd.2014.07.026. Epub 2014 Oct 14.

22.

What level of sodium intake worsens renal outcomes?

Lipkowitz MS, Wilcox CS.

Am J Hypertens. 2014 Oct;27(10):1243-4. doi: 10.1093/ajh/hpu067. Epub 2014 May 10. No abstract available.

23.

Heritable influence of DBH on adrenergic and renal function: twin and disease studies.

Pasha DN, Davis JT, Rao F, Chen Y, Wen G, Fung MM, Mahata M, Zhang K, Trzebinska D, Mustapic M, Hightower CM, Lipkowitz MS, Ji M, Ziegler MG, Nievergelt CM, O'Connor DT.

PLoS One. 2013 Dec 31;8(12):e82956. doi: 10.1371/journal.pone.0082956. eCollection 2013. Erratum in: PLoS One. 2014;9(6):e100351.

24.

A within-patient analysis for time-varying risk factors of CKD progression.

Li L, Chang A, Rostand SG, Hebert L, Appel LJ, Astor BC, Lipkowitz MS, Wright JT, Kendrick C, Wang X, Greene TH.

J Am Soc Nephrol. 2014 Mar;25(3):606-13. doi: 10.1681/ASN.2013050464. Epub 2013 Nov 14.

25.

APOL1 risk variants, race, and progression of chronic kidney disease.

Parsa A, Kao WH, Xie D, Astor BC, Li M, Hsu CY, Feldman HI, Parekh RS, Kusek JW, Greene TH, Fink JC, Anderson AH, Choi MJ, Wright JT Jr, Lash JP, Freedman BI, Ojo A, Winkler CA, Raj DS, Kopp JB, He J, Jensvold NG, Tao K, Lipkowitz MS, Appel LJ; AASK Study Investigators; CRIC Study Investigators.

N Engl J Med. 2013 Dec 5;369(23):2183-96. doi: 10.1056/NEJMoa1310345. Epub 2013 Nov 9.

26.

Association of phosphodiesterase 4 polymorphism (rs702553) with blood pressure in the African American Study of Kidney Disease and Hypertension Genomics Study.

Anthony EG, Richard E, Lipkowitz MS, Kelley ST, Alcaraz JE, Shaffer RA, Bhatnagar V.

Pharmacogenet Genomics. 2013 Aug;23(8):442-4. doi: 10.1097/FPC.0b013e3283636840.

PMID:
23778321
27.

Serum potassium predicts time to blood pressure response among African Americans with hypertensive nephrosclerosis.

Bhalla M, Aziz H, Richard E, Lipkowitz MS, Bhatnagar V.

J Hum Hypertens. 2013 Jun;27(6):393-6. doi: 10.1038/jhh.2012.47. Epub 2012 Nov 15.

28.

Relationship between ambulatory BP and clinical outcomes in patients with hypertensive CKD.

Gabbai FB, Rahman M, Hu B, Appel LJ, Charleston J, Contreras G, Faulkner ML, Hiremath L, Jamerson KA, Lea JP, Lipkowitz MS, Pogue VA, Rostand SG, Smogorzewski MJ, Wright JT, Greene T, Gassman J, Wang X, Phillips RA; African American Study of Kidney Disease and Hypertension (AASK) Study Group.

Clin J Am Soc Nephrol. 2012 Nov;7(11):1770-6. doi: 10.2215/CJN.11301111. Epub 2012 Aug 30.

29.

Minocycline-induced renal polyarteritis nodosa.

Tabriziani H, Wilcox CS, Gilbert ON, Lipkowitz MS.

BMJ Case Rep. 2012 Aug 13;2012. pii: bcr2012006503. doi: 10.1136/bcr-2012-006503.

30.

Paraoxonase 1 (PON1) C/T-108 association with longitudinal mean arterial blood pressure.

Bhatnagar V, Liu L, Nievergelt CM, Richard E, Brophy VH, Pandey B, Lipkowitz MS, O'Connor DT.

Am J Hypertens. 2012 Nov;25(11):1188-94. doi: 10.1038/ajh.2012.106. Epub 2012 Aug 2.

31.

Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans.

Lipkowitz MS, Freedman BI, Langefeld CD, Comeau ME, Bowden DW, Kao WH, Astor BC, Bottinger EP, Iyengar SK, Klotman PE, Freedman RG, Zhang W, Parekh RS, Choi MJ, Nelson GW, Winkler CA, Kopp JB; SK Investigators.

Kidney Int. 2013 Jan;83(1):114-20. doi: 10.1038/ki.2012.263. Epub 2012 Jul 25.

32.

Kidney function can improve in patients with hypertensive CKD.

Hu B, Gadegbeku C, Lipkowitz MS, Rostand S, Lewis J, Wright JT, Appel LJ, Greene T, Gassman J, Astor BC; African-American Study of Kidney Disease and Hypertension Group.

J Am Soc Nephrol. 2012 Apr;23(4):706-13. doi: 10.1681/ASN.2011050456. Epub 2012 Mar 8.

33.

Regulation of uric acid excretion by the kidney.

Lipkowitz MS.

Curr Rheumatol Rep. 2012 Apr;14(2):179-88. doi: 10.1007/s11926-012-0240-z. Review.

PMID:
22359229
34.

Longitudinal progression trajectory of GFR among patients with CKD.

Li L, Astor BC, Lewis J, Hu B, Appel LJ, Lipkowitz MS, Toto RD, Wang X, Wright JT Jr, Greene TH.

Am J Kidney Dis. 2012 Apr;59(4):504-12. doi: 10.1053/j.ajkd.2011.12.009. Epub 2012 Jan 26.

35.

Genetic association and gene-gene interaction analyses in African American dialysis patients with nondiabetic nephropathy.

Bostrom MA, Kao WH, Li M, Abboud HE, Adler SG, Iyengar SK, Kimmel PL, Hanson RL, Nicholas SB, Rasooly RS, Sedor JR, Coresh J, Kohn OF, Leehey DJ, Thornley-Brown D, Bottinger EP, Lipkowitz MS, Meoni LA, Klag MJ, Lu L, Hicks PJ, Langefeld CD, Parekh RS, Bowden DW, Freedman BI; Family Investigation of Nephropathy and Diabetes (FIND) Research Group.

Am J Kidney Dis. 2012 Feb;59(2):210-21. doi: 10.1053/j.ajkd.2011.09.020. Epub 2011 Nov 25.

36.

Methylenetetrahydrofolate reductase (MTHFR) polymorphism A1298C (Glu429Ala) predicts decline in renal function over time in the African-American Study of Kidney Disease and Hypertension (AASK) Trial and Veterans Affairs Hypertension Cohort (VAHC).

Fung MM, Salem RM, Lipkowitz MS, Bhatnagar V, Pandey B, Schork NJ, O'Connor DT; AASK Study Investigators.

Nephrol Dial Transplant. 2012 Jan;27(1):197-205. doi: 10.1093/ndt/gfr257. Epub 2011 May 25.

37.

Limitations of analyses based on achieved blood pressure: lessons from the African American study of kidney disease and hypertension trial.

Davis EM, Appel LJ, Wang X, Greene T, Astor BC, Rahman M, Toto R, Lipkowitz MS, Pogue VA, Wright JT Jr; African American Study of Kidney Disease and Hypertension Research Collaborative Group.

Hypertension. 2011 Jun;57(6):1061-8. doi: 10.1161/HYPERTENSIONAHA.111.169367. Epub 2011 May 9.

38.

Common charge-shift mutation Glu65Lys in K+ channel β₁-Subunit KCNMB1: pleiotropic consequences for glomerular filtration rate and progressive renal disease.

Chen Y, Salem RM, Rao F, Fung MM, Bhatnagar V, Pandey B, Mahata M, Waalen J, Nievergelt CM, Lipkowitz MS, Hamilton BA, Mahata SK, O'Connor DT.

Am J Nephrol. 2010;32(5):414-24. doi: 10.1159/000320131. Epub 2010 Sep 23.

39.

Intensive blood-pressure control in hypertensive chronic kidney disease.

Appel LJ, Wright JT Jr, Greene T, Agodoa LY, Astor BC, Bakris GL, Cleveland WH, Charleston J, Contreras G, Faulkner ML, Gabbai FB, Gassman JJ, Hebert LA, Jamerson KA, Kopple JD, Kusek JW, Lash JP, Lea JP, Lewis JB, Lipkowitz MS, Massry SG, Miller ER, Norris K, Phillips RA, Pogue VA, Randall OS, Rostand SG, Smogorzewski MJ, Toto RD, Wang X; AASK Collaborative Research Group.

N Engl J Med. 2010 Sep 2;363(10):918-29. doi: 10.1056/NEJMoa0910975.

40.

Progression of chronic kidney disease: Adrenergic genetic influence on glomerular filtration rate decline in hypertensive nephrosclerosis.

Chen Y, Lipkowitz MS, Salem RM, Fung MM, Bhatnagar V, Mahata M, Nievergelt CM, Rao F, Mahata SK, Schork NJ, Hicks PJ, Bowden DW, Freedman BI, Brophy VH, O'Connor DT; AASK.

Am J Nephrol. 2010;32(1):23-30. doi: 10.1159/000313927. Epub 2010 May 19.

41.

CRP polymorphisms and progression of chronic kidney disease in African Americans.

Hung AM, Crawford DC, Griffin MR, Brown-Gentry K, Lipkowitz MS, Siew ED, Cavanaugh K, Lewis JB, Ikizler TA; AASK Study Group.

Clin J Am Soc Nephrol. 2010 Jan;5(1):24-33. doi: 10.2215/CJN.01900309. Epub 2009 Dec 3.

42.

CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease.

Bhatnagar V, Garcia EP, O'Connor DT, Brophy VH, Alcaraz J, Richard E, Bakris GL, Middleton JP, Norris KC, Wright J, Hiremath L, Contreras G, Appel LJ, Lipkowitz MS; AASK Study Investigators.

Am J Nephrol. 2010;31(2):95-103. doi: 10.1159/000258688. Epub 2009 Nov 12.

43.

Adrenergic beta-1 receptor genetic variation predicts longitudinal rate of GFR decline in hypertensive nephrosclerosis.

Fung MM, Chen Y, Lipkowitz MS, Salem RM, Bhatnagar V, Mahata M, Nievergelt CM, Rao F, Mahata SK, Schork NJ, Brophy VH, O'Connor DT; AASK Co-Investigators.

Nephrol Dial Transplant. 2009 Dec;24(12):3677-86. doi: 10.1093/ndt/gfp471. Epub 2009 Sep 10.

44.

Chromogranin A regulates renal function by triggering Weibel-Palade body exocytosis.

Chen Y, Mahata M, Rao F, Khandrika S, Courel M, Fung MM, Zhang K, Stridsberg M, Ziegler MG, Hamilton BA, Lipkowitz MS, Taupenot L, Nievergelt C, Mahata SK, O'Connor DT.

J Am Soc Nephrol. 2009 Jul;20(7):1623-32. doi: 10.1681/ASN.2008111148. Epub 2009 Jun 11.

45.

G-protein-coupled receptor kinase 4 polymorphisms and blood pressure response to metoprolol among African Americans: sex-specificity and interactions.

Bhatnagar V, O'Connor DT, Brophy VH, Schork NJ, Richard E, Salem RM, Nievergelt CM, Bakris GL, Middleton JP, Norris KC, Wright J, Hiremath L, Contreras G, Appel LJ, Lipkowitz MS; AASK Study Investigators.

Am J Hypertens. 2009 Mar;22(3):332-8. doi: 10.1038/ajh.2008.341. Epub 2009 Jan 1.

46.

Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans.

Appel LJ, Wright JT Jr, Greene T, Kusek JW, Lewis JB, Wang X, Lipkowitz MS, Norris KC, Bakris GL, Rahman M, Contreras G, Rostand SG, Kopple JD, Gabbai FB, Schulman GI, Gassman JJ, Charleston J, Agodoa LY; African American Study of Kidney Disease and Hypertension Collaborative Research Group.

Arch Intern Med. 2008 Apr 28;168(8):832-9. doi: 10.1001/archinte.168.8.832.

47.

Association of a CYP4A11 variant and blood pressure in black men.

Gainer JV, Lipkowitz MS, Yu C, Waterman MR, Dawson EP, Capdevila JH, Brown NJ; AASK Study Group.

J Am Soc Nephrol. 2008 Aug;19(8):1606-12. doi: 10.1681/ASN.2008010063. Epub 2008 Apr 2.

48.

Angiotensin-converting enzyme gene polymorphism predicts the time-course of blood pressure response to angiotensin converting enzyme inhibition in the AASK trial.

Bhatnagar V, O'Connor DT, Schork NJ, Salem RM, Nievergelt CM, Rana BK, Smith DW, Bakris GL, Middleton JP, Norris KC, Wright JT, Cheek D, Hiremath L, Contreras G, Appel LJ, Lipkowitz MS.

J Hypertens. 2007 Oct;25(10):2082-92.

49.

The role of ambulatory BP monitoring in clinical care.

Ommen ES, Lipkowitz MS.

Geriatrics. 2007 Aug;62(8):11-4. Review.

PMID:
17668959
50.

How accurate are formulas that calculate creatinine clearance?

Rafey MA, Lipkowitz MS.

Nat Clin Pract Urol. 2007 Apr;4(4):188-9. Epub 2007 Mar 6. No abstract available.

PMID:
17342097

Supplemental Content

Loading ...
Support Center